Acutaas Chemicals (ACUTAAS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
17 May, 2026Business overview and market position
Offers over 610 products, serving ~600 customers in 55+ countries across pharmaceuticals, semiconductors, battery, and commodity chemicals.
Holds 50–90% global market share in key pharmaceutical intermediates and is India's only manufacturer of photoresist chemicals.
Operates five manufacturing facilities, with ongoing expansion in South Korea for advanced semiconductor chemicals.
Over 90% of products are backward integrated to basic chemicals, ensuring supply chain control.
Achieved EcoVadis Platinum rating, reflecting top-tier sustainability practices.
Strategic evolution and milestones
Transitioned from a small lab in 1998 to a global specialty chemicals leader, with major expansions and acquisitions from 2004 to 2025.
Entered new verticals such as battery additives and semiconductors through acquisitions and joint ventures.
Surpassed ₹10,000 million in sales in 2025 and rebranded to reflect a focus on specialty and custom solutions.
Recognized for innovation, export performance, and leadership, with multiple industry awards.
Business segments and differentiation
Pharmaceutical intermediates: Focus on CDMO, chronic therapies, and early off-patent product development; 95% of products serve chronic segments.
Specialty chemicals: Only Indian supplier of photoresist chemicals, with advanced purity and niche market focus.
Battery chemicals: First Indian manufacturer of electrolyte additives, with strong export orientation and 10+ products in pipeline.
Commodity chemicals: Over 400 customers, portfolio diversification, and resilience during global overcapacity.
Latest events from Acutaas Chemicals
- Record FY26 growth, margin expansion, South Korea JV, and Rs. 2.5/share dividend recommended.ACUTAAS
Q4 25/2611 May 2026 - Record Q3 revenue, profit, and margins led to upgraded FY26 growth guidance and major JV investment.ACUTAAS
Q3 25/2613 Apr 2026 - Q1 FY25 revenue up 16.6% YoY; margins down, 25% growth guidance and net debt zero achieved.ACUTAAS
Q1 24/2510 Feb 2026 - Q1 FY26 revenue up 17.3% YoY, profit surged, and new South Korea JV supports 25% growth outlook.ACUTAAS
Q1 25/263 Feb 2026 - Q3 FY25 revenue up 65.2% YoY, PAT more than doubled, and FY25 growth guidance raised to 35%.ACUTAAS
Q3 24/2520 Dec 2025 - Q2 FY 2025 revenue up 43.2% YoY, PAT up 155%, and FY 2025 growth guidance raised to 30%.ACUTAAS
Q2 24/2519 Dec 2025 - FY25 revenue surpassed ₹10,000 million, with strong profit growth and 25% growth targeted for FY26.ACUTAAS
Q4 24/2519 Dec 2025 - Q2 FY26 saw strong revenue and profit growth, major investments, and a share split.ACUTAAS
Q2 25/2618 Dec 2025